Improving estimates of event incidence over time in populations exposed to other events -: Application to three large databases

被引:38
作者
Alberti, C
Métivier, F
Landais, P
Thervet, E
Legendre, C
Chevret, S
机构
[1] Hop St Louis, Dept Biostat & Informat Med, F-75475 Paris 10, France
[2] Hop St Louis, Serv Nephrol, F-75475 Paris, France
[3] Hop Necker Enfants Malad, Unite Biostat & Informat Med, F-75015 Paris, France
关键词
cohort studies; competing risk; cumulative incidence; Kaplan-Meier curve; survival data;
D O I
10.1016/S0895-4356(03)00058-1
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The Kaplan-Meier (KM) method is commonly used to estimate the incidence of an event over time. It assumes independence between the event of interest and any competing event that precludes the event of interest to occur. However, when the competing event is death without the event of interest, censoring these patients will affect the incidence of the event of interest by modifying the number of exposed patients, so that KM results will be misleading. Three prospective cohorts were studied: (1) 657 renal transplant recipients, (2) 262 children with acute leukemia who received bone marrow transplants, and (3) 8,353 intensive care patients. The main outcome measures were kidney graft loss, leukemia relapse, and ICU-acquired infection, respectively, with death before the main outcome as the competing event. The incidence of each main outcome was overestimated by the KM method. The magnitude of overestimation ranged from 3% to 30%, and varied with baseline patient characteristics and follow-up duration, with-most of this variation being related to the rate of the competing event. A competing-risk approach must be used to analyze the risk of events other than death in cohort studies, particularly when mortality rates are high. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:536 / 545
页数:10
相关论文
共 29 条
[1]   COMPETING EVENTS DETERMINING RELAPSE-FREE SURVIVAL IN LIMITED SMALL-CELL LUNG-CARCINOMA [J].
ARRIAGADA, R ;
KRAMAR, A ;
LECHEVALIER, T ;
DECREMOUX, H .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (03) :447-451
[2]   ESTIMATES OF ABSOLUTE CAUSE-SPECIFIC RISK IN COHORT STUDIES [J].
BENICHOU, J ;
GAIL, MH .
BIOMETRICS, 1990, 46 (03) :813-826
[3]   Determinants of chronic renal allograft rejection in cyclosporine-treated recipients [J].
Flechner, SM ;
Modlin, CS ;
Serrano, DP ;
Goldfarb, DA ;
Papajcik, D ;
Mastroianni, B ;
Goormastic, M ;
Novick, AC .
TRANSPLANTATION, 1996, 62 (09) :1235-1241
[4]  
GAYNOR JJ, 1993, J AM STAT ASSOC, V88, P602
[5]   IMPROVED METHODOLOGY FOR ANALYZING LOCAL AND DISTANT RECURRENCE [J].
GELMAN, R ;
GELBER, R ;
HENDERSON, IC ;
COLEMAN, CN ;
HARRIS, JR .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (03) :548-555
[6]  
Gjertson D W, 1997, Clin Transpl, P337
[7]  
Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO
[8]  
2-F
[9]   A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].
GRAY, RJ .
ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154
[10]   Improved graft survival after renal transplantation in the United States, 1988 to 1996. [J].
Hariharan, S ;
Johnson, CP ;
Bresnahan, BA ;
Taranto, SE ;
McIntosh, MJ ;
Stablein, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (09) :605-612